Purdue Pharma
Purdue Pharma OxyContin Marketing
Estimated impact: $8.3B
Purdue Pharma aggressively marketed OxyContin as a low-addiction-risk painkiller, contributing to the opioid epidemic that has killed over 500,000 Americans. The company knew its claims about addiction risk were false but continued its marketing campaign for over two decades, driven by confirmation bias around its own flawed studies.
Decision context
Whether to market OxyContin with claims of low addiction potential based on limited and misleading evidence, and whether to continue aggressive sales tactics as addiction reports mounted.
Biases present in the decision
Toxic combinations
- Echo Chamber
Reference class base rates
Across all 146 curated case studies in our library:
Lessons learned
- Confirmation bias in interpreting addiction data allowed Purdue to maintain claims that contradicted real-world evidence for over two decades.
- Loss aversion around a profitable product line can cause companies to ignore catastrophic societal harm.
- Regulatory capture and aggressive lobbying can delay corrective action by years, amplifying public health damage.
Source: DOJ Settlement with Purdue Pharma (2020); Patrick Radden Keefe, "Empire of Pain" (2021) (Case Study)
See what we'd flag in your next strategic memo.
Upload a strategic memo or board deck. Get the same bias audit you just saw for Purdue Pharma, on your own high-stakes call, in under 60 seconds.
Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.
Ready to audit your own memo right now? Create a free account →